image

Hemophilia Market Report Scope & Overview:

The Hemophilia Market size was valued at USD 13.6 billion in 2023 and is expected to reach USD 22.50 billion by 2031 and grow at a CAGR of 6.5 % over the forecast period of 2024-2031.

Hemophilia is a health condition in which the body does not make enough protein, protein can be studied as clotting factor the basic role of clotting is to help your blood form clots. Hemophilia is said to be a blood disorder which further makes less blood clot and because of which risk of excessive bleeding occurs, the common symptoms and signs of hemophilia includes bleeding into joints, bleeding in skin and also according to the reports hemophilia can result into death if the bleeding tends to happen in the vital organ like brain. The two most common type of hemophilia includes Hemophilia A and Hemophila B the major reason behind the cause of the disease is because of change or mutation in the genes. As we mentioned earlier clotting factor is the major reason for the hemophilia the low levels of clotting factor i.e., Factor 8 and factor 9 can be considered as the major reason behind the hemophila.

Hemophilia Market Revenue Analysis

Get More Information on Hemophilia Market - Request Sample Report

This Hemphilia Market report is divided into two segments by therapy type and by indication, by indication includes type A type B type C type A all are related to the different clotting factor i.e., 8, 9 and 11 these mentioned factors determine the symptoms which an individual may face.

Impact Of covid 19

Covid 19 affected the market negatively, the rules and guidelines imposed by the government made it difficult for the patients to visit the hospitals and get access to the doctors physically, the whole healthcare industry was busy with the covid patients as a matter of priority. The percentage of visiting patients gradually dropped on a bigger scale which also impacted the Hemophilia market. The pandemic also caused the decline of demand for the hemophilia medicines which also contributed to the negative zone of this particular market.

Market Dynamics

Drivers

  • Rise in the awareness of hemophilia disease.

The rising cases of the hemophilia all around the globe increases the awareness of the hemophilia disease and rising initiative taken by the government and the health organizations to promote the hemophilia care treatment has a positive impact on the market.

Restrain

  • High cost of hemophlia treatment

The fact that the cost of the hemophilia care is expensive which acts as a barrier in the underdeveloped and the emerging countries because of the economic instability and also the fact that the global outbreak impacts the economic condition on a macro and a micro level which affects the market in a negative way.

Opportunity

  • Technological advancement in the treatment of hemophilia disease.

The rise in the technological advancement because of the rising demand for the treatment of the hempohilia disease is the major driving factor, the continues innovation which will help the health experts to provide proper treatment to the patients, and also the focus regarding the future upgradation will drive the market during the forecasted period.

Challenge

  • The treatment of the hemophilia is time consuming and the access of the hemophilia care in the emerging countries is less comparatively.

According to our analysis people who are suffering from the hemophilia disease in the emerging and undeveloped countries have to face lot of issues in terms of false commitments from the government, and the economy issues of the nation which impacts the market in terms of building infrastructure providing good facilities for the patients.

Impact of Ongoing Recession

Recession can affect the hemophilia market in a negative manner as the high cost of the hemophilia care treatment is the restraining factor for that particular market, recession causes economic disturbance all around the globe and that to on a personal level, during the 2009 recession records say that recession caused change in people’s perspective, this report will give you an exact brief about how recession impacts the hemophilia market.

Key Market Segmentation

By Therapy Type

  • Replacement Therapy

  • Clotting Factors

    • Plasma-derived factor concentrate

    • Recombinant factor concentrate

  • Medications

    • Hemlibra

    • DDAVP/Stimate

    • Amicar

    • Fibrin Sealants

    • Others

  • Physical Therapy

  • Immune Tolerance Induction (ITI) Therapy

  • Vaccination

  • Gene Therapy

  • Others

By Indications

  • Type A

  • Type B

  • Type C

  • Type D

Regional Analysis

North America will be the dominating region for hemophilia market because of the rising cases and the continuous initiatives taken by the government to promote and create awareness will drive the market,

APAC region will also show a good growth during the forecasted period because of the rising awareness of the disease and the continuous upgradation in the developed cities of the APAC region will contribute to the growth of the hemophilia market.

Hemophilia Market By Region

Need any customization research on Hemophilia Market - Enquiry Now

REGIONAL COVERAGE:

  • North America

    • USA

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • The Netherlands

    • Rest of Europe

  • Asia-Pacific

    • Japan

    • south Korea

    • China

    • India

    • Australia

    • Rest of Asia-Pacific

  • The Middle East & Africa

    • Israel

    • UAE

    • South Africa

    • Rest of Middle East & Africa

  • Latin America

    • Brazil

    • Argentina

    • Rest of Latin America           

Key Players

The major key players Pfizer, uniQure N.V., CSL, Genentech USA, Inc., Sanofi, Takeda Pharmaceutical Company Limited., Baxalta, Bayer, Novo Nordisk, Alnylam Pharmaceuticals, Biogen and Other Players.

Sanofi-Company Financial Analysis

Company Landscape Analysis

Hemophilia Market Report Scope:
Report Attributes Details
Market Size in 2023  US$ 13.6 Bn
Market Size by 2031  US$ 22.50 Bn
CAGR   CAGR of 5.2% From 2024 to 2031
Base Year  2023
Forecast Period  2024-2031
Historical Data  2020-2022
Report Scope & Coverage Market Size, Segments Analysis, Competitive  Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
Key Segments • By Therapy Type (Replacement Therapy, Clotting Factors, Medications, Physical Therapy, Immune Tolerance Induction (ITI) Therapy, Vaccination, Gene Therapy, Others)
• By Indications (Type A, Type B, Type C, Type D)
Regional Analysis/Coverage North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
Company Profiles Pfizer, uniQure N.V., CSL, Genentech USA, Inc., Sanofi, Takeda Pharmaceutical Company Limited., Baxalta, Bayer, Novo Nordisk, Alnylam Pharmaceuticals, Biogen.
Key Drivers • Rise in the awareness of hemophilia disease.
Market Opportunities • Technological advancement in the treatment of hemophilia disease.

 

Frequently Asked Questions

Ans: The Hemophilia Market size was valued at USD 13.6 Bn in 2023.

Rise in the awareness of hemophilia disease.

North America will be the dominating region for hemophilia market

Covid -19 affected the market negatively

Ans: The Hemophilia Market is to grow at a CAGR of 6.5% Over the Forecast Period 2024-2031.

Table of Contents

1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions

2. Research Methodology

3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges

4. Impact Analysis
4.1 COVID-19 Impact Analysis
4.2 Impact of Ongoing Recession
4.2.1 Introduction
4.2.2 Impact on major economies
4.2.2.1 US
4.2.2.2 Canada
4.2.2.3 Germany
4.2.2.4 France
4.2.2.5 United Kingdom
4.2.2.6 China
4.2.2.7 Japan
4.2.2.8 South Korea
4.2.2.9 Rest of the World

5. Value Chain Analysis

6. Porter’s 5 forces model

7. PEST Analysis

8. Hemophilia Market Segmentation, By Therapy Type
8.1 Replacement Therapy
8.2 Clotting Factors
8.2.1 Plasma-derived factor concentrate
8.2.2 Recombinant factor concentrate
8.3 Medications
8.3.1 Hemlibra
8.3.2 DDAVP/Stimate
8.3.3 Amicar
8.3.4 Fibrin Sealants
8.3.5 Others
8.4 Physical Therapy
8.5 Immune Tolerance Induction (ITI) Therapy
8.6 Vaccination
8.7 Gene Therapy
8.8 Others

9. Hemophilia Market Segmentation, by Indications
9.1 Type A
9.2 Type B
9.3 Type C
9.4 Type D

10. Regional Analysis
10.1 Introduction
10.2 North America
10.2.1 North America Hemophilia Market by Country
10.2.2North America Hemophilia Market by Therapy Type
10.2.3 North America Hemophilia Market by Indication
10.2.4 USA
10.2.4.1 USA Hemophilia Market by Therapy Type
10.2.4.2 USA Hemophilia Market by Indication
10.2.5 Canada
10.2.5.1 Canada Hemophilia Market by Therapy Type
10.2.5.2 Canada Hemophilia Market by Indication
10.2.6 Mexico
10.2.6.1 Mexico Hemophilia Market by Therapy Type
10.2.6.2 Mexico Hemophilia Market by Indication
10.3 Europe
10.3.1 Europe Hemophilia Market by Country
1.3.3.2 Europe Hemophilia Market by Therapy Type
10.3.3 Europe Hemophilia Market by Indication
10.3.4 Germany
10.3.4.1 Germany Hemophilia Market by Therapy Type
10.3.4.2 Germany Hemophilia Market by Indication
10.3.5 UK
10.3.5.1 UK Hemophilia Market by Therapy Type
10.3.5.2 UK Hemophilia Market by Indication
10.3.6 France
10.3.6.1 France Hemophilia Market by Therapy Type
10.3.6.2 France Hemophilia Market by Indication
10.3.7 Italy
10.3.7.1 Italy Hemophilia Market by Therapy Type
10.3.7.2 Italy Hemophilia Market by Indication
10.3.8 Spain
10.3.8.1 Spain Hemophilia Market by Therapy Type
10.3.8.2 Spain Hemophilia Market by Indication
10.3.9 The Netherlands
10.3.9.1 Netherlands Hemophilia Market by Therapy Type
10.3.9.2 Netherlands Hemophilia Market by Indication
10.3.10 Rest of Europe
10.3.10.1 Rest of Europe Hemophilia Market by Therapy Type
10.3.10.2 Rest of Europe Hemophilia Market by Indication
10.4 Asia-Pacific
10.4.1 Asia Pacific Hemophilia Market by Country
10.4.2 Asia Pacific Hemophilia Market by Therapy Type
10.4.3 Asia Pacific Hemophilia Market by Indication
10.4.4 Japan
10.4.4.1 Japan Hemophilia Market by Therapy Type
10.4.4.2 Japan Hemophilia Market by Indication
10.4.5 South Korea
10.4.5.1 South Korea Hemophilia Market by Therapy Type
10.4.5.2 South Korea Hemophilia Market by Indication
10.4.6 China
10.4.6.1 China Hemophilia Market by Therapy Type
10.4.6.2 China Hemophilia Market by Indication
10.4.7 India
10.4.7.1 India Hemophilia Market by Therapy Type
10.4.7.2 India Hemophilia Market by Indication
10.4.8 Australia
10.4.8.1 Australia Hemophilia Market by Therapy Type
10.4.8.2 Australia Hemophilia Market by Indication
10.4.9 Rest of Asia-Pacific
10.4.9.1 APAC Hemophilia Market by Therapy Type
10.4.9.2 APAC Hemophilia Market by Indication
10.5 The Middle East & Africa
10.5.1 The Middle East & Africa Hemophilia Market by Country
10.5.2 The Middle East & Africa Hemophilia Market by Therapy Type
10.5.3 The Middle East & Africa Hemophilia Market by Indication
10.5.4 Israel
10.5.4.1 Israel Hemophilia Market by Therapy Type
10.5.4.2 Israel Hemophilia Market by Indication
10.5.5 UAE
10.5.5.1 UAE Hemophilia Market by Therapy Type
10.5.5.2 UAE Hemophilia Market by Indication
10.5.6 South Africa
10.5.6.1 South Africa Hemophilia Market by Therapy Type
10.5.6.2 South Africa Hemophilia Market by Indication
10.5.7 Rest of Middle East & Africa
10.5.7.1 Rest of Middle East & Asia Hemophilia Market by Therapy Type
10.5.7.2 Rest of Middle East & Asia Hemophilia Market by Indication
10.6 Latin America
10.6.1 Latin America Hemophilia Market by Country
10.6.2 Latin America Hemophilia Market by Therapy Type
10.6.3 Latin America Hemophilia Market by Indication
10.6.4 Brazil
10.6.4.1 Brazil Hemophilia Market by Therapy Type
10.6.4.2 Brazil Africa Hemophilia Market by Indication
10.6.5 Argentina
10.6.5.1 Argentina Hemophilia Market by Therapy Type
10.6.5.2 Argentina Hemophilia Market by Indication
10.6.6 Rest of Latin America
10.6.6.1 Rest of Latin America Hemophilia Market by Therapy Type
10.6.6.2 Rest of Latin America Hemophilia Market by Indication

11. Company Profile
11.1 Pfizer
11.1.1 Market Overview
11.1.2 Financials
11.1.3 Product/Services/Offerings
11.1.4 SWOT Analysis
11.1.5 The SNS View
11.2 uniQure N.V
11.2.1 Market Overview
11.2.2 Financials
11.2.3 Product/Services/Offerings
11.2.4 SWOT Analysis
11.2.5 The SNS View
11.3 CSL
11.3.1 Market Overview
11.3.2 Financials
11.3.3 Product/Services/Offerings
11.3.4 SWOT Analysis
11.3.5 The SNS View
11.4 Genentech USA, Inc
11.4.1 Market Overview
11.4.2 Financials
11.4.3 Product/Services/Offerings
11.4.4 SWOT Analysis
11.4.5 The SNS View
11.5 Sanofi
11.5.1 Market Overview
11.5.2 Financials
11.5.3 Product/Services/Offerings
11.5.4 SWOT Analysis
11.5.5 The SNS View
11.6 Takeda Pharmaceutical Company Limited
11.6.1 Market Overview
11.6.2 Financials
11.6.3 Product/Services/Offerings
11.6.4 SWOT Analysis
11.6.5 The SNS View
11.7 Baxalta
11.7.1 Market Overview
11.7.2 Financials
11.7.3 Product/Services/Offerings
11.7.4 SWOT Analysis
11.7.5 The SNS View
11.8 Bayer
11.8.1 Market Overview
11.8.2 Financials
11.8.3 Product/Services/Offerings
11.8.4 SWOT Analysis
11.8.5 The SNS View
11.9 Novo Nordisk
11.9.1 Market Overview
11.9.2 Financials
11.9.3 Product/Services/Offerings
11.9.4 SWOT Analysis
11.9.5 The SNS View
11.10 Alnylam Pharmaceuticals
11.10.1 Market Overview
11.10.2 Financials
11.10.3 Product/Services/Offerings
11.10.4 SWOT Analysis
11.10.5 The SNS View
11.10 Biogen
11.10.1 Market Overview
11.10.2 Financials
11.10.3 Product/Services/Offerings
11.10.4 SWOT Analysis
11.10.5 The SNS View

12. Competitive Landscape
12.1 Competitive Benchmarking
12.2 Market Share Analysis
12.3 Recent Developments

13. Use Cases and Practice’s

14. Conclusion

An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.

Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.

 

The 5 steps process:

Step 1: Secondary Research:

Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.

Secondary Research

Step 2: Primary Research

When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data.  This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.

We at SNS Insider have divided Primary Research into 2 parts.

Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.

This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.

Primary Research

Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.

Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.

Step 3: Data Bank Validation

Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.

Data Bank Validation

Step 4: QA/QC Process

After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.

Step 5: Final QC/QA Process:

This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.

Start a Conversation

Hi! Click one of our member below to chat on Phone